Natus Medical Announces 2011 Third Quarter Financial Results
Natus Medical Incorporated (NASDAQ:BABY) today announced financial results for the three and nine months ended September 30, 2011.
The Company reported revenue of $51.3 million for the third quarter ended September 30, 2011, compared to revenue of $53.2 million reported in the comparable quarter of the previous year. Embla Systems, which the company acquired on September 15, 2011, contributed $1.3 million of revenue. Net income was $153,000 or $0.01 per diluted share, compared to net income of $3.6 million or $0.12 per diluted share for the third quarter of 2010.
For the nine months ended September 30, 2011, the Company reported net income of $5.6 million, or $0.19 per diluted share, compared to net income of $6.7 million, or $0.23 per diluted share, for the comparable period in 2010.
The Company reported non-GAAP earnings per share of $0.07 per diluted share for the third quarter of 2011 compared to $0.16 per diluted share for the same period in 2010. Non-GAAP net income was $2.1 million in the 2011 period compared to $4.8 million in the third quarter of 2010. For the nine months ended September 30, 2011 non-GAAP net income was $9.9 million, or $0.34 per share, compared to $12.0 million or $0.41 per share for the same period in 2010.
In commenting on the third quarter revenue results, Jim Hawkins, Chief Executive Officer of the Company said, “The third quarter revenue shortfall, which is consistent with the expected results we announced on October 10th, was primarily attributable to our neurology business where we experienced order delays in both domestic and international markets and also a reduction in order size in the United States. Our Medix subsidiary, with newborn care products sold primarily in Latin America, also experienced a shortfall that was due to delayed orders. Our other newborn care products, including our newborn hearing screening, newborn brain monitoring, and phototherapy product lines performed to expectations in the third quarter.”Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
